Immunomodulatory Nanoparticles for Modulating Arthritis Flares

• Published in: ACS nano 2024-01, Vol.18 (3), p.1892-1906
• Main Authors: Johnson, Wade T., McBride, David, Kerr, Matthew, Nguyen, Anders, Zoccheddu, Martina, Bollmann, Miriam, Wei, Xiaofu, Jones, Ryan M., Wang, Wei, Svensson, Mattias N. D., Bottini, Nunzio, Shah, Nisarg J.
• Format: Article
• Language: English
• Subjects: Animals; Autoimmune Diseases; Calcitriol - metabolism; Cattle; Cytokines - metabolism; Dendritic Cells; Immunity; Immunologi inom det medicinska området; Immunology in the medical area; Lactates; Mice; Nanoparticles - chemistry; Polyethylene Glycols; Symptom Flare Up; X-Ray Microtomography
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.3c05298

Disease-modifying drugs have improved the treatment for autoimmune joint disorders, such as rheumatoid arthritis, but inflammatory flares are a common experience. This work reports the development and application of flare-modulating poly­(lactic-co-glycolic acid)-poly­(ethylene glycol)-maleimide (PLGA-PEG-MAL)-based nanoparticles conjugated with joint-relevant peptide antigens, aggrecan70–84 and type 2 bovine collagen256–270. Peptide-conjugated PLGA-PEG-MAL nanoparticles encapsulated calcitriol, which acted as an immunoregulatory agent, and were termed calcitriol-loaded nanoparticles (CLNP). CLNP had a ∼200 nm hydrodynamic diameter with a low polydispersity index. In vitro, CLNP induced phenotypic changes in bone marrow derived dendritic cells (DC), reducing the expression of costimulatory and major histocompatibility complex class II molecules, and proinflammatory cytokines. Bulk RNA sequencing of DC showed that CLNP enhanced expression of Ctla4, a gene associated with downregulation of immune responses. In vivo, CLNP accumulated in the proximal lymph nodes after intramuscular injection. Administration of CLNP was not associated with changes in peripheral blood cell numbers or cytokine levels. In the collagen-induced arthritis and SKG mouse models of autoimmune joint disorders, CLNP reduced clinical scores, prevented bone erosion, and preserved cartilage proteoglycan, as assessed by high-resolution microcomputed tomography and histomorphometry analysis. The disease protective effects were associated with increased CTLA-4 expression in joint-localized DC and CD4+ T cells but without generalized suppression of T cell-dependent immune response. The results support the potential of CLNP as modulators of disease flares in autoimmune arthropathies.